Volume 3.15 | Apr 17

Hematopoiesis News 3.15, April 17, 2012
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Results provide improved understanding of microenvironmental regulation of normal and leukemic long-term hematopoietic stem cells and their response to imatinib in chronic myelogenous leukemia. [Cancer Cell] Abstract | Press Release

Hematopoietic Course for Cord Blood - Learn More and Register

PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Connexin-43 in the Osteogenic BM Niche Regulates Its Cellular Composition and the Bidirectional Traffic of Hematopoietic Stem Cells and Progenitors
To elucidate the biologic function of connexin-43 (Cx43) in a hematopoietic microenvironment and its influence in hematopoietic stem cell activity, researchers studied the hematopoietic function in an in vivo model of constitutive deficiency of Cx43 in osteoblasts and osteogenic progenitors. [Blood] Abstract

Spry1 As a Novel Regulator of Erythropoiesis, EPO/EPOR Target, and Supressor of Jak2
Studies implicate Spry1 as a novel regulator of erythropoiesis during anemia, transducer of erythropoietin receptor (EPOR) signals and candidate suppressor of Jak2 activity. [Blood] Abstract

Heme-Regulated eIF2α Kinase Activated Atf4 Signaling Pathway in Oxidative Stress and Erythropoiesis
Scientists report the role of the heme-regulated eIF2α kinase-activated Atf4 signaling pathway in reducing oxidative stress and in promoting erythroid differentiation during erythropoiesis. [Blood] Abstract

In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells
Researchers sought to genetically manipulate human hematopoietic stem cells such that they differentiate into mature cytotoxic T lymphocytes that will kill HIV infected cells. [PLoS Pathog] Abstract | Press Release

Lipid Raft Redistribution and Morphological Cell Polarization Are Separable Processes Providing a Basis for Hematopoietic Stem and Progenitor Cell Migration
Scientists addressed impacts of protein synthesis, hematopoietic stem and progenitor cells (HSPC) trafficking, cytoskeleton organization or lipid raft integrity on the establishment and maintenance of the cell polarity of human HSPCs. [Int J Biochem Cell Biol] Abstract

Stromal-Derived IL-6 Alters the Balance of Myeloerythroid Progenitors during Toxoplasma gondii Infection
Data suggest that bone marrow stromal cells regulate the hematopoietic changes during inflammation via IL-6. [J Leukoc Biol] Abstract

Efficient Commitment to Functional CD34+ Progenitor Cells from Human Bone Marrow Mesenchymal Stem-Cell-Derived Induced Pluripotent Stem Cells
Researchers propose that CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential, could be efficiently obtained from induced pluripotent stem cells derived from human bone marrow mesenchymal stem cells with defined factors. [PLoS One] Abstract

Deferasirox Exposure Induces Reactive Oxygen Species and Reduces Growth and Viability of Myelodysplastic Hematopoietic Progenitors
The effect of deferasirox on CD34+ hematopoietic progenitors from myelodysplastic syndrome patients was examined. [Leuk Res] Abstract

Rapamycin Enhances Dimethyl Sulfoxide-Mediated Growth Arrest in Human Myelogenous Leukemia Cells
Scientists tested for the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide on growth arrest and differentiation of acute myelogenous leukemia cells. [Leuk Lymphoma] Abstract

CLINICAL RESEARCH

High Activity of Sorafenib in FLT3-ITD-Positive Acute Myeloid Leukemia (AML) Synergizes with Allo-Immune Effects to Induce Sustained Responses
Researchers evaluated sorafenib monotherapy in 65 FLT3-ITD-postive AML patients treated at 23 centers. [Leukemia] Abstract

Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 Molecule
The results of a first-in-man Phase I trial of intranodal direct injection of adenovirus encoding chimeric CD154 in patients with chronic lymphocytic leukemia to evaluate toxicity, safety, and tolerability are reported. [Cancer Res] Abstract

Watch the Webinar: How Three Chimerism Groups Saved Time, Effort, and Money with RoboSep

INDUSTRY NEWS

VistaGen Licenses Breakthrough Stem Cell Culture Technology to Speed Development of Drug Screening and Cell Therapy for Immune System Disorders
VistaGen Therapeutics, Inc. has licensed breakthrough stem cell culture technology from the McEwen Centre for Regenerative Medicine. VistaGen will be utilizing the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, with the goal of developing drug screening and cell therapy applications for human blood system disorders. [VistaGen Therapeutics, Inc.] Press Release

Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS(TM) in CD30-Positive Malignancies
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company announced that they have formed a collaboration with Ventana Medical Systems, Inc. (Ventana). [Seattle Genetics, Inc.] Press Release

Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine
Cyclacel Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,124,593 which grants claims to a specified method of administration of sapacitabine with patent exclusivity until July 2030. [Cyclacel Pharmaceuticals, Inc.] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW ISEH – Society for Hematology and Stem Cells: 41st Annual Scientific Meeting
August 23-26, 2012
Amsterdam, Netherlands

Visit our events page to see a complete list of events in the hematopoietic community
JOB OPPORTUNITIES

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies Inc.)

Scientist – Hematology (STEMCELL Technologies Inc.)

Scientist – hPSC (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Principal Investigators in Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Fellow in Stem Cells and Cancer (Tsinghua University)


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us